Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 37INDUSTRY 8OTHER_GOV 4FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 42Colonic Neoplasms 14Colonic Polyps 13Carcinoma, Hepatocellular 9Adenoma 7Rectal Neoplasms 5Liver Neoplasms 5Fibrosis 5Barrett Esophagus 5Neoplasms 4Lung Neoplasms 4Esophageal Neoplasms 4Breast Neoplasms 4Adenocarcinoma Of Esophagus 4Health Education 3Gastroesophageal Reflux 3Urinary Bladder Neoplasms 2Patient Compliance 2Ovarian Neoplasms 2Esophageal Squamous Cell Carcinoma 2Adenomatous Polyps 2Tobacco Use 1Stroke 1Renal Insufficiency, Chronic 1Rare Diseases 1Pulmonary Disease, Chronic Obstructive 1Proteinuria 1Patient Satisfaction 1Patient Preference 1Patient Acceptance of Health Care 1

Interventions

Infliximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
FED × Crohn Disease × Gastrointestinal × Clear all
NCT00004941 2015-03-25

Phase III Randomized Study of Anti-Tumor Necrosis Factor Chimeric Monoclonal Antibody (cA2) for Patients With Enterocutaneous Fistulae as a Complication of Crohn's Disease

FDA Office of Orphan Products Development

Phase 3 Completed
94 enrolled
Gastrointestinal

Crohn Disease, Gastrointestinal Diseases, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡